Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Aytu Biopharma (AYTU) over the last 14 years, with Q4 2025 value amounting to $40.2 million.

  • Aytu Biopharma's Accumulated Expenses rose 199.13% to $40.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $40.2 million, marking a year-over-year increase of 199.13%. This contributed to the annual value of $38.2 million for FY2025, which is 5.51% up from last year.
  • Aytu Biopharma's Accumulated Expenses amounted to $40.2 million in Q4 2025, which was up 199.13% from $36.7 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Accumulated Expenses registered a high of $57.2 million during Q2 2021, and its lowest value of $33.7 million during Q3 2024.
  • Its 5-year average for Accumulated Expenses is $43.9 million, with a median of $42.5 million in 2021.
  • As far as peak fluctuations go, Aytu Biopharma's Accumulated Expenses surged by 54810.33% in 2021, and later plummeted by 2381.21% in 2022.
  • Over the past 5 years, Aytu Biopharma's Accumulated Expenses (Quarter) stood at $50.7 million in 2021, then decreased by 18.68% to $41.2 million in 2022, then grew by 5.33% to $43.4 million in 2023, then fell by 9.31% to $39.4 million in 2024, then grew by 1.99% to $40.2 million in 2025.
  • Its last three reported values are $40.2 million in Q4 2025, $36.7 million for Q3 2025, and $38.2 million during Q2 2025.